Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1827-1834

  Buckheit Jr , Robert W ^a   White, E Lucile ^a   Fliakas Boltz, Valerie ^a   Russell, Julie ^a   Stup, Tracy L ^a   Kinjerski, Tracy L ^a   Osterling, Mark C ^a   Weigand, Ann ^a   Bader, John P ^b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALANOLIDE A; CALANOLIDE B; DIHYDROCALANOLIDE B; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOMER; PRIORITY JOURNAL; STEREOISOMERISM; VIRUS INHIBITION;

EID: 0344172806     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1827     Document Type: Article

References (31)

1. Bader, J. P., J. B. McMahon, R. J. Schultz, V. L. Narayanan, J. B. Pierce, W. A. Harrison, O. S. Weislow, C. F. Midelfort, S. F. Stinson, and M. R. Boyd. 1991. Oxathiin carhoxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. USA 88:6740-6744.
2. Baizarini, J., A. Karlsson, M. J. Perez-Perez, M. J. Camarasa, W. G. Tarpley, and E. De Clercq. 1993. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:5353-5359.
3. Balzarini, J., A. Karlsson, A. M. Vandamme, M. J. Perez-Perez, H. Zhang, L. Vrang, B. Oberg, K. Backbro, T. Unge, and A. San-Felix. 1993. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-((ert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)]-beta-D- pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:6952-6956.
4. Boyer, P. L., M. J. Currens, J. B. McMahon, M. R. Boyd, and S. H. Hughes. 1993. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 67:2412-2420.
5. Buckheit, R. W., Jr. Unpublished results.
6. Buckheit, R. W., Jr., M. J. Snow, V. Fliakas-Boltz, T. L. Kinjerski, J. D. Russell, L. A. Pallansch, W. G. Brouwer, and S. S. Yang. Highly potent oxathiin carboxanilide derivatives with efficacy against human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor-resistant virus isolates. Antimicrob. Agents Chemother., in press.
7. Buckheit, R. W., Jr., V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, C. A. Pyle, E. L. White, B. J. Bowdon, J. B. McMahon, M. R. Boyd, J. P. Bader, D. G. Nickell, H. Barth, and T. K. Antonucci. 1994. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antivir. Res. 25:43-56.
8. Buckheit, R. W., Jr., V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, T. L. Stup, C. A. Pyle, E. L. White, J. B. McMahon, M. J. Currens, M. R. Boyd, and J. P. Bader. 1995. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antivir. Res. 2•: 117-132.
9. Buckheit, R. W., Jr., V. Fliakas-Boltz, S. Yeagy-Bargo, O. Weislow, D. L. Mayers, P. L. Boyer, S. H. Hughes, B. C. Pan, S. H. Chu, and J. P. Bader. 1995. Resistance to 1-[2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology 210:186-193.
10. Buckheit, R. W., Jr., J. Germany-Decker, M. G. Hollingshead, L. B. Allen, W. M. Shannon, P. A. Janssen, and M. A. Chirigos. 1993. Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents. AIDS Res. Hum. Retroviruses 9:1097-1106.
11. Buckhelt, R. W., Jr., M. G. Hollingshead, J. Germany-Decker, E. L. White, J. B. McMahon, L. B. Allen, L. J. Ross, W. D. Decker, L. Westbrook, and W. M. Shannon. 1993. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antivir. Res. 21:247-265.
12. Buckheit, R. W., Jr., T. L. Kinjerski, V. Fliakas-Boltz, J. D. Russell, T. L. Stup, L. A. Pallansch, W. G. Brouwer, D. C. Dao, W. A. Harrison, R. J. Schultz, J. P. Bader, and S. S. Yang. 1995. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39:2718-2727.
13. Byrnes, V. W., V. V. Sardana, W. A. Schleif, J. H. Condra, J. A. Waterbury, J. A. Wolfgang, W. J. Long, C. L. Schneider, A. J. Schlabach, and B. S. Wolanski. 1993. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1576-1579.
14. Carr, A., and D. A. Cooper. 1998. Current clinical experience with nevirapine for HIV infection. Adv. Exp. Med. Biol. 394:299-304.
15. Cohen, K. A., J. Hopkins, R. H. Ingraham, C. Pargellis, J. C. Wu, D. E. Palladino, P. Kinkade, T. C. Warren, S. Rogers, and J. Adams. 1991. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J. Biol. Chem. 266:14670-14674.
16. Condra, J. H., E. A. Emini, L. Gotlib, D. J. Graham, A. J. Schlabach, J. A. Wolfgang, R. J. Colonno, and V. V. Sardana. 1992. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob. Agents Chemother. 36:1441-1446.
17. Currens, M. J., R. J. Gulakowski, J. M. Mariner, R. A. Moran, R. W. Buckheit, Jr., K. R. Gustafson, J. B. McMahon, and M. R. Boyd. 1996. Antiviral activity mechanism of action of calanolide A against the human immunodeficiency virus. J. Pharmacol. Exp. Ther. 279:645-651.
18. De Clercq, E. 1996. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Med. Virol. 6:97-117.
19. De Clercq, E. 1998. The role of non-nuclcoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antivir. Res. 38:153-179.
20. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
21. Grob, P. M., J. C. Wu, K. A. Cohen, R. H. Ingraham, C. K. Shih, K. D. Hargrave, T. L. McTague, and V. J. Merluzzi. 1992. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses 8:145-152.
22. Halliday, S. M., C. S. Lackman-Smith, W. D. Decker, J. P. Bader, W. G. Rice, D. J. Clanton, and R. W. Buckheit, Jr. 1996. Inhibition of HIV replication by the sulfonated dye resobene. Antivir. Res. 33:41-53.
23. Hizi, A., R. Tal, M. Shaharabany, M. J. Currens, M. R. Boyd, S. H. Hughes, and J. B. McMahon. 1993. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1037-1042.
24. Kashman, Y., K. R. Gustafson, R. W. Fuller, J. H. Cardellina, J. B. McMahon, M. J. Currens, R. W. Buckheit, Jr., S. H. Hughes, G. M. Cragg, and M. R. Boyd. 1992. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J. Med. Chem. 35:2735-2743. (Erratum, 36:1110, 1993.)
25. McMahon, J. B., R. W. Buckheit, Jr., R. J. Gulakowski, M. J. Currens, D. T. Vistica, R. H. Shoemaker, S. F. Stinson, J. D. Russell, J. P. Bader, V. L. Narayanan, R. J. Shultz, W. G. Brouwer, E. E. Felauer, and M. R. Boyd. 1995. Biological and biochemical anti-human immunodeficiency virus activity of UC-38, a new nonnucleoside reverse transcriptase inhibitor. J. Pharmacol. Exp. Ther. 276:298-305.
26. McMahon, J. B., R. J. Gulakowski, O. S. Weislow, R. J. Schultz, V. L. Narayanan, D. J. Clanton, R. Pedemonte, F. W. Wassmundt, R. W. Buckheit, Jr., and W. D. Decker. 1993. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37: 754-760.
27. Mellors, J. W., B. A. Larder, and R. F. Schinazi. 1995. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antivir. News 3:8-13.
28. Parker, W. B., E. L. White, S. C. Shaddix, L. J. Ross, R. W. Buckheit, Jr., J. M. Germany, J. A. Secrist, R. Vince, and W. M. Shannon. 1991. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymcrascs αβ, and gamma by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J. Biol. Chem. 246:1754-1762.
29. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-206.
30. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, and J. C. Kappes. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N. Engl. J. Med. 329:1065-1072.
31. White, E. L., W. B. Parker, L. J. Ross, and W. M. Shannon. 1993. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogs. Antivir. Res. 22:295-308.